# A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

> **NCT04068792** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 22 (actual)

## Conditions studied

- Respiratory Syncytial Viruses

## Interventions

- **OTHER:** RSV Mobile Application
- **DRUG:** Placebo
- **DRUG:** JNJ-53718678 2.5 mg/kg
- **DRUG:** JNJ-53718678 3 mg/kg
- **DRUG:** JNJ-53718678 4.5 mg/kg

## Key facts

- **NCT ID:** NCT04068792
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-10
- **Primary completion:** 2021-05-15
- **Final completion:** 2021-05-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068792, "A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04068792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*